NBIX Q3 2026: Robust Growth, but Net Price and Dilution Questions Linger

What happened

Neurocrine Biosciences posted Q3 2026 EPS of $3.29 on revenue of $1.12 billion, up 41% year over year, driven by INGREZZA's 17% growth to $801 million. The quarter also featured the VYKAT XR launch and the Soleno Therapeutics acquisition, which add to the rare disease pipeline but introduce integration and dilution risks. While headline numbers beat, management provided no clarity on INGREZZA net price trends, a key concern from prior filings that flagged 2025 net price erosion from market access investments. The DOJ civil investigative demand remains unresolved, and the salesforce expansion productivity is still unproven despite the top-line beat. Overall, the quarter supports the core franchise strength but does not resolve the thesis-critical unit economics and legal overhangs.

Implication

Given the prior base case implied $150 with a 50% probability contingent on 2026 INGREZZA reaching $2.75B and CRENESSITY above $450M, today's $801M quarterly INGREZZA suggests a run-rate near $3.2B, which is positive but may include price concessions. The new products and acquisition increase the company's fixed cost base and could pressure margins if integration falters. The DOJ investigation remains a black swan that could restrict marketing or lead to fines, which the market currently appears to downplay. Maintain a cautious stance: if next quarter shows net price per Rx stable and VYKAT XR adoption accelerating, the thesis strengthens; otherwise, the stock's multiple could compress. Reassess after the next earnings call for explicit commentary on gross-to-net and salesforce productivity.

Thesis delta

Thesis shifts from 'wait for volume-led growth without net price erosion' to 'growth is occurring, but durability is uncertain amid new product dilution and legal overhang.' The Soleno acquisition and VYKAT XR launch add optionality but also increase execution risk and near-term costs. Overall, the potential buy rating is maintained but with lower conviction until net price and DOJ clarity emerge.